A PHASE 1, OPEN-LABEL, 4-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF [14C]PF-07328948 AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-07328948 IN HEALTHY MALE ADULT PARTICIPANTS USING A [14C]-MICROTRACER APPROACH
Latest Information Update: 30 Apr 2026
At a glance
- Drugs PF 07328948 (Primary) ; PF 07328948 (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 27 Apr 2026 Status changed from not yet recruiting to recruiting.
- 09 Apr 2026 New trial record